---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021739"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:19:02.609253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reports positive MISSION Phase 2 results: 64.7% ORR at Week 25, increases to 94.1% in follow-up

## Summary
- ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.
- CRR (UPCR ≤0.5) achieved in 35.3% at end of treatment, rising to 41.2% during safety follow-up (Week 29 & 37).
- Mean background corticosteroid use reduced by 53%; by Week 13, 82.4% on ≤10 mg/day steroids.
- SLEDAI-2K reduced from 11.3 baseline to 6.5 at EOT; Physician Global Assessment from 57.2 to 23.9.
- Zetomipzomib well-tolerated; no Grade 3 infections; early terminations in 4/21 patients.

## SEC filing metadata
- accession: 0000950170-22-021739
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/0000950170-22-021739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017022021739/kzr-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021739
- JSON: https://secwatch.observer/filing/0000950170-22-021739.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.